NKGN reorienting their autologous program towards non-cancer diseases. Some intriguing compassionate use results on Alzheimer's but N was low, now expanding to phase 1/2a to see if results can be repeated. Still have allo program for cancer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.